Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: Insights from the SOLVD Treatment trial

Abstract: Background: Angiotensin-converting enzyme inhibitors improve outcomes in systolic heart failure (SHF). However, doubts linger about their effect in SHF patients with chronic kidney disease (CKD).Methods: In the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial, 2569 ambulatory chronic HF patients with left ventricular ejection fraction ≤35% and serum creatinine level ≤2.5mg/dl were randomized to receive either placebo (n=1284) or enalapril (n=1285). Of the 2502 patients with baseline serum creatinine data, 1036 had CKD (estimated glomerular filtration rate

Source: International Journal of Cardiology - January 18, 2012 Category: Cardiology Authors: C. Barrett Bowling, Paul W. Sanders, Richard M. Allman, William J. Rogers, Kanan Patel, Inmaculada B. Aban, Michael W. Rich, Bertram Pitt, Michel White, George C. Bakris, Gregg C. Fonarow, Ali Ahmed Tags: Original Articles Source Type: research